Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study

Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting BASEL, Switzerland, March 23, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the American Association for...

Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma BASEL, Switzerland, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient has been dosed in the OMNIA-1 study – a Phase I/II study...